T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.
about
Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancerPhenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcomaImmune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?Immune Infiltration and Prostate CancerMetastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapyTherapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advancesCombining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapyImmunotherapy for prostate cancer: recent developments and future challengesTherapeutic cancer vaccines: past, present, and futureFrom bench to bedside: immunotherapy for prostate cancerRecent advances in therapeutic cancer vaccinesAndrogens alter T-cell immunity by inhibiting T-helper 1 differentiationImmune modulation through 4-1BB enhances SIV vaccine protection in non-human primates against SIVmac251 challengePhase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implicationsProstate cancer and inflammation: the evidence.Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment.Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses.In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.Testosterone regulates tight junction proteins and influences prostatic autoimmune responsesAn update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactionsCancer immunotherapy: sipuleucel-T and beyond.Immunotherapy for the treatment of prostate cancer.Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancerBuilding on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.National practice patterns and time trends in androgen ablation for localized prostate cancer.Androgen receptor, ccl2, and epithelial-mesenchymal transition: A dangerous affair in the tumor microenvironmentA combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacyAndrogen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription.CTLA-4: new insights into its biological function and use in tumor immunotherapy.Prostate cancer as a model for tumour immunotherapy.Intensity-modulated pelvic radiation therapy and simultaneous integrated boost to the prostate area in patients with high-risk prostate cancer: a preliminary report of disease control.An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate.Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.Prostate cancer immunotherapy.A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.
P2860
Q21136183-BEC2E018-2FAD-4CBA-8526-D975351EF2A1Q24814867-9C5F2FC2-C113-4563-9B99-18069DE2847DQ26740601-7C8BEDF0-C0FB-427D-ADD8-5CBB77E1C85CQ26798412-F4DC49B6-A3D9-4899-9588-17E8A8FF205BQ26825053-0C725381-C088-45EA-B6E6-16368BC37227Q26827475-77FD8280-644F-4074-84E3-C14114BB6FEFQ26851608-61446124-888A-4833-A153-A35511B1B42AQ26852388-B4CBDC91-F0E9-41DC-92B0-301BF042A532Q26863283-35FAF34B-2691-45E5-A61A-354CD3187051Q26864390-F2555EDD-F62E-425C-9D59-68CA782F00E7Q27025266-2940AA58-DF08-4C1B-B966-067DD5E59BA5Q28655545-2DA8F9DD-F471-48C5-9003-A3D83583F075Q28740359-365C93CF-831A-4E59-993F-6CCE6C6AC3A3Q33440805-34991DD9-2C20-45F2-9D20-D619161A62C9Q33621393-D6A3C041-2970-40C6-B7C1-092E54923932Q33642321-8DA4EDA9-4300-4B60-BF68-0F9D56E46448Q33756662-F357808F-6430-4A4D-842C-5DB35FDDADE5Q33777002-610B4580-2D0D-4092-82ED-F62DF218D845Q33798326-4F1207C4-570E-4E40-B9C4-A646C7F6DFD2Q33837085-A5FC0098-F4A8-40A7-B538-23A6D50CBE48Q33872776-41A7E2F6-1EDB-42AC-B819-66F2463A5650Q33962057-0721D827-5493-4F72-89A7-7937DE5DA3A2Q34048630-CB4E77E0-3624-4B68-BF32-F332741764CBQ34158070-A3B559D4-F7B3-462F-BE16-9825D9212BD6Q34186928-03CC5E88-AB65-477B-A3EB-7829B9E929BAQ34297813-E0925957-CC64-47FB-BB43-38BC7B1EF61DQ34321844-FADFD6B0-A4D2-4897-AAA8-E9927FE1F008Q34363769-82B2A60C-AA7E-4FCB-B4B5-1CCA9F4FF6AFQ34373051-F5991E03-3797-4103-A2C9-98645D4BEF9AQ34403480-2CD1A855-BF02-4675-82A7-BBF07515FF49Q34443548-C760C6B0-8C29-480F-B57E-3E8C60B15784Q34546701-58580671-3275-40AC-9A8A-B43855CEF1BEQ34711491-7F7F0C38-3A45-4AD1-9502-70AF1845E034Q34856875-4828E81E-A7BE-41D4-927A-477ABD38768DQ34998545-6FE7BC2B-F534-424F-9325-7FA24805B2B3Q35106324-3AA4094C-310B-4D9A-9A7C-27A5109048FAQ35567212-950B9BA4-B5BE-45ED-9CEE-D8989BA927EEQ35688425-6DE0878F-9E1D-4BB9-89F5-1327EDA6A7B3Q35756538-C644FFA1-5121-4F9C-8F6F-C80D3989CF36Q35835108-D85C0BE2-9F6F-4B16-ACFA-E747681C0CA9
P2860
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
T cell infiltration of the pro ...... patients with prostate cancer.
@ast
T cell infiltration of the pro ...... patients with prostate cancer.
@en
type
label
T cell infiltration of the pro ...... patients with prostate cancer.
@ast
T cell infiltration of the pro ...... patients with prostate cancer.
@en
prefLabel
T cell infiltration of the pro ...... patients with prostate cancer.
@ast
T cell infiltration of the pro ...... patients with prostate cancer.
@en
P2093
P2860
P356
P1476
T cell infiltration of the pro ...... patients with prostate cancer.
@en
P2093
B K Bodner
E M Wojcik
M Mercader
R C Flanigan
R G Manecke
P2860
P304
14565-14570
P356
10.1073/PNAS.251140998
P407
P577
2001-12-01T00:00:00Z